• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Omar Ford

Omar Ford

Articles

ARTICLES

Titan Spine gains clearance for its Endoskeleton TCS

Feb. 13, 2015
By Omar Ford

NewCo on the Go: Aortica develops more personalized approach for treating AAA patients

Feb. 12, 2015
By Omar Ford
Each year between 150,000 and 180,000 people in the U.S. are diagnosed with abdominal aortic aneurysms (AAA). Endovascular aortic repair (EVAR) is significantly less invasive than open surgery and is associated with a mortality rate six times lower. Patients recover faster, leave the hospital sooner, and return to activities of normal daily life more quickly.
Read More

Cohera Medical completes significant milestone with approval of TissuGlu

Feb. 10, 2015
By Omar Ford
Just what is a "quiet earthquake"? According to Cohera Medical (Pittsburgh), a developer of surgical adhesives and sealants, its TissuGlu application could be considered as one, because it has the potential to eliminate the need for post-surgical drains in abdominoplasty procedures. The private firm had plenty of reasons to speak about TissuGlu on Monday, as it revealed that it has received FDA approval for the technology.
Read More

Seismic M&A activity last year catapults firms into 2015

Feb. 9, 2015
By Omar Ford

Medtronic secures approval for Pipeline Flex embolization device

Feb. 6, 2015
By Omar Ford

Alliqua BioMedical to acquire Celleration for $30.4 million

Feb. 4, 2015
By Omar Ford

MedShape receives FDA nod for FastForward Bone Tether Plate

Feb. 3, 2015
By Omar Ford

MDD's Diagnostics Extra

Jan. 30, 2015
By Omar Ford

Abiomed moves forward with HDE approval of Impella RP

Jan. 30, 2015
By Omar Ford

Lombard launches ARCHYTAS registry for EVAR of abdominal aneurysms

Jan. 29, 2015
By Omar Ford
View All Articles by Omar Ford

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • Antibodies

    Abbvie gains rights to IGI’s trispecific ISB-2001 in $1.9B+ deal

    BioWorld
    Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation (IGI) Inc. has signed with Abbvie Inc. a...
  • PTAB hands Exact a loss in Geneoscopy patent dispute

    BioWorld MedTech
    The med tech patent wars opened a new front in the region of screening tests for colorectal cancer, pitting Exact Sciences Corp., of Madison, Wisc., against St....
  • Document illustration

    US FDA finally taking the wraps off CRLs

    BioWorld
    It’s been more than seven years in coming, but the U.S. FDA is at last making public at least some of the complete response letters (CRLs) it’s sent to drug and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe